AbCellera Biologics (ABCL) Interest Expenses (2020 - 2026)

AbCellera Biologics' Interest Expenses history runs 7 years deep, the most recent figure standing at $3.7 million for Q1 2026.

• Quarterly Interest Expenses changed N/A year-over-year to $3.7 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $3.7 million (changed N/A YoY) and the FY2025 annual result came in at $56.2 million, up 12.67% from the prior year.
• Interest Expenses was $3.7 million for Q1 2026 at AbCellera Biologics, down from $56.2 million in the prior quarter.
• Across five years, Interest Expenses topped out at $56.2 million in Q4 2025 and bottomed at $3.7 million in Q1 2026.
• A 5-year average of $13.8 million and a median of $4.2 million in 2022 frame the typical range for Interest Expenses.
• Annual changes were most pronounced in 2022 — Interest Expenses soared 13311.0% — and 2023, when it sank 72.22%.
• AbCellera Biologics' Interest Expenses stood at $13.4 million in 2022, then sank by 72.22% to $3.7 million in 2023, then soared by 1239.84% to $49.9 million in 2024, then increased by 12.67% to $56.2 million in 2025, then tumbled by 93.44% to $3.7 million in 2026.
• Business Quant data shows ABCL's Interest Expenses at $3.7 million in Q1 2026, $56.2 million in Q4 2025, and $49.9 million in Q4 2024.